GlassScriptPhysician profile
Thomas Joseph Maino
NPI 1659323640
$7,387.31
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,641 · 2020: $733 · 2021: $1,710 · 2022: $1,446 · 2023: $714 · 2024: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,907.00 | 2019 | |
| Gemini Mountain Medical, LLC | $733.58 | 2019 | |
| Abbvie INC. | $669.62 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $564.40 | 2022-2024 | Qelbree, Qelbree, Tlando |
| Lilly USA, LLC | $493.57 | 2020-2023 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $428.17 | 2020-2022 | |
| Glaxosmithkline, LLC. | $379.12 | 2020-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $318.17 | 2020-2023 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $228.16 | 2021-2023 | |
| Amarin Pharma, INC. | $168.53 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $167.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.36 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $129.35 | 2021-2022 | |
| Pfizer INC. | $126.23 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $108.13 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.77 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.20 | 2022 | |
| Upsher-Smith Laboratories LLC | $79.48 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.94 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.38 | 2021-2022 | |
| Exact Sciences Corporation | $58.43 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $53.58 | 2023 | Accrufer |
| Eisai INC. | $40.80 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $37.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.72 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $26.70 | 2022 | |
| Allergan, INC. | $23.75 | 2020 | |
| Hikma Pharmaceuticals USA | $18.50 | 2023 | Ryaltris |
| Almatica Pharma LLC | $16.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.73 | 2020 | |
| Nabriva Therapeutics, Plc | $15.11 | 2021 | |
| Currax Pharmaceuticals LLC | $14.93 | 2021 | |
| Halozyme INC | $14.06 | 2023 | |
| Merck Sharp & Dohme LLC | $13.80 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.48 | 2023 | Xifaxan |
| Genentech USA, INC. | $13.20 | 2020 | |
| Mylan Specialty L.P. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Maino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.